CASI Pharmaceuticals (CASIF) Income from Continuing Operations (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported Income from Continuing Operations of 77193000.0 for Q4 2025, down 459.98% on a YoY basis from 21443796.32 in Q4 2024, and down 668.78% quarter-over-quarter from 10041000.0 in Q3 2025.
CASI Pharmaceuticals (CASIF) Income from Continuing Operations (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Income from Continuing Operations for 4 years, with the latest figure at 77193000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 459.98% year-over-year to 77193000.0; the trailing twelve-month figure through Dec 2025 stood at 109376000.0 (down 162.59% YoY), and the FY2025 full-year result was 45871000.0, down 801.38% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 77193000.0, down from 10041000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 16117000.0 in Q4 2023, with the low at 77193000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 11883437.5 across 4 years, with a median of 9298000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 207.24% — and 2025, when it sank 459.98%.
- CASI Pharmaceuticals' Income from Continuing Operations stood at 15029000.0 in 2022, then surged by 207.24% to 16117000.0 in 2023, then tumbled by 185.53% to 13785000.0 in 2024, then slumped by 459.98% to 77193000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 77193000.0 (Q4 2025), 10041000.0 (Q3 2025), and 11566000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | -56.48 Mn |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -77.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -77.19 Mn |
| Sep 30, 2025 | -10.04 Mn |
| Jun 30, 2025 | -11.57 Mn |
| Mar 31, 2025 | -10.58 Mn |
| Dec 31, 2024 | -13.79 Mn |
| Sep 30, 2024 | -9.05 Mn |
| Jun 30, 2024 | -9.17 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | 16.12 Mn |
| Sep 30, 2023 | -4.59 Mn |
| Jun 30, 2023 | -9.43 Mn |
| Mar 31, 2023 | -7.21 Mn |
| Dec 31, 2022 | -15.03 Mn |
| Sep 30, 2022 | -5.62 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.96 Mn |